Views & Analysis Innovative contracting in Europe: a Trojan Horse? By Mary Iyiola & Agnieszka Janska, with additional consultation by Smita Sealey & Barry Farrimond
News FDA won't approve Summit, Akeso's ivonescimab The FDA has said it cannot approve Summit /Akeso's ivonescimab, delaying a drug that could usher in a new era of dual-acting cancer immunotherapies.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.